Important medical technology available for license or aquisition

Used daily upon waking, the Biosymtec Monitor will detect and predict developing • non-respiratory infections, • reductions in lung function (exacerbations), and • respiratory infections (differentiating between the three) all before symptoms and clinical signs, such as a fever, occur.

The Biosymtec Monitor detects infections such as • urinary tract infections, • bronchitis, • influenza, • pneumonia, • COVID-19 and variants, days before symptoms, allowing for early medical intervention including the use of antivirals and antibiotics, when they are most effective.

“I am going to prescribe this Biosymtec Monitor for your use upon waking each day. The Biosymtec Monitor is an antesigna device; that is, it detects infections before you have symptoms or clinical signs of an infection.  Early detection will get you to me before any developing symptoms cause you to go to the hospital.”

The Biosymtec Monitor is kept by the bedside so that it can be used upon waking, before getting out of bed. The dual probes are placed under the tongue, straddling the frenulum. A special core temperature is taken. Upon rising the patient blows hard through the monitor.
An AI algorithm delivers immediate results which are shown on the display.

The results are also immediately forwarded to the Biosymtec System where they are stored, graphed and the resulting graph is promptly made available to the physician's computer or tablet and to the patient's smartphone. The special graph shows exactly what has been displayed on the Biosymtec Monitor; in this case all green in each column.

Monitor

 

“It is our belief the virus leaked sometime in late August or early September 2019,” said Michael McCaul - lead Republican on the U.S. House of Representatives Foreign Affairs Committee

"This is an actual Biosymtec graph of a patient we later suspected of having one of the first cases of COVID-19 in the U.S.   He acquired the infection on a train ride between Lancaster and Philadephia, Pennsylvania.   Very similar to COVID, it began with a cough, then a fever developed, followed by a respiratory infection on October 30.   On the left is a Biosymtec Monitor displaying a respiratory infection."

Front Page

The Biosymtec Monitor will replace the thermometer and peak-flow meter used now by pulmonary patients. Unlike the thermometer and peak-flow meter, the Biosymtec Monitor will also forward results to the patients’ physicians.

Will the patient still need a thermometer to check for a fever? No, the Biosymtec Monitor will serve also as a unique fever thermometer, indicating low grade or high grade fevers.

Cleaning the spirometer assembly is easy. It can be removed from the bottom of the Biosymtec Monitor, washed in soapy water, rinsed and air dried before being returned. The replaceable power cell is thereby also made accessible.

Monitor

 

“The Biosymtec Monitor was designed as an oral platform which can be further designed to acquire many other biometric readings:

  • Detect non-respiratory infections before symptoms,
  • Detect lung function issues before exacerbations,
  • Detect respiratory infections before symptoms, and keep COPD and asthma patients out of the hospital. Those will be the first three initial capabilities of the Biosymtec Monitor. The following are planned:
  • Read and produce the patients electrocardiogram (EKG),
  • Measure Forced Expiratory Volume at 1 second (FEV1),
  • Measure Forced vital capacity (FVC),
  • Measure Fractional Exhaled Nitric Oxide (FeNO),
  • Measure Exhaled Oxygen percentage (eO%),
  • Measure waking heart rate (HR),
  • Measure Blood Oxygen Saturation (SpO2),
  • Measure Respiration Rate (RR), and possibly,
  • Read Blood Sugar levels with transmissive technology (others are working on it),
    We have also been studying (through published papers) the possibility that the Biosymtec Monitor could:
  • Detect lung cancer through exhaled breath (latest science news), and even,
  • Cure some cancers using orally introduced EMF! It's being done in Germany.
  • ekg

    These are the primary markets for the Biosymtec Monitor, because patients with COPD, including chronic bronchitis, asthma and emphysema, must be treated early to avoid respiratory infections developing into pneumonia. They must be treated by their physicians before their symptoms get so bad they find themselves in a hospital ER.

    There are over 40 million with COPD and asthma in the U.S., 300 million worldwide, and the numbers are growing. During the research studies done in China, a Health Bureau physician said emphatically, after we commented on the local air polution, "In 10 years, everybody sick, in 10 years, everybody sick."

    There are many other markets.

    Heart Failure (CHF) patients must learn early if they have any infection, because infections further weaken their hearts.

    As Cystic Fibrosis (CF) primarily affects the lungs, these patients are prone to chest infections. Early detection and early treatment are key.

    Healthcare Workers

    Teachers

    Development Status: The product research engineering of the Biosymtec Monitor has been completed, and the project is ready for the Final Design Phase followed by tooling. The cost of the Final Design Phase is estimated to be $500K (actual quotations from quality sources were obtained).

    Patent Status: A Provisional Patent Application has been submitted by patent counsel to the USPTO. The document must be updated before applying for Patent.

    Ownership: The Biosymtec Technology, including all aspects of the Biosymtec Monitor, the AI Algorithm, and Copyrighted graph template, are solely owned by
    John L. Beiswenger (dba Beiswenger Research).

    Transferable Materials:
          •   AutoCAD file (Concept Engineering Layout),
          •   Non-functional model (Parts 3D printed from Layout),
          •   The AI Algorithm,
          •   Virtual Biosymtec Monitor using the AI Algorithm,
          •   Copyrighted Graph Template,
          •   Provisional Patent Application.

    License available: Terms and Provisions negotiable.

    Available for Aquisition: Terms negotiable.

    Project Support Offer: John L. Beiswenger will accept employment (remote, if beyond daily driving distance) for a period of one year. Beiswenger's experience (and full Biosymtec Monitor opportunity presentation) is available through Beiswenger.com.

    Exploded view rendered from CAD layout.